In 2022, a phase III clinical trial was performed using a DIGP with 99mTc-PSMA-I&S in robot-assisted PSMA-RGS, including 20 patients with recurrent PCa 52 (Figure 6). Here, FOLH1 is linked to posterior cortical atrophy.